Oncology Focused Company's Rich Pipeline and Partnering Strategy

Oncology Focused Specialty Pharmaceutical Company Rich Product Pipeline – Active Partnering Strategy

[object Object],[object Object],Safe Harbor Statement

[object Object],[object Object],[object Object],[object Object],[object Object],Corporate Strategy & Highlights Late Stage Oncology Pipeline; Emphasis on Strategic Partnering; Focus on Building Shareholder Value

Late Stage Oncology Pipeline ~ $500 M Pexiganan ~ $350 M FDA Approved MuGard ™ Non-core Dermatology Assets Being Partnered/Sold >$600 M Thiarabine >$100 M EcoNail Product Oncology Pipeline Pre-clinical IND Phase 1 Phase 2 Phase 3 Potential ProLindac™ ~ $3 B Angiolix mAb >$1 B Other preclinical Includes Prodrax and phenylbutyrate > $500 M VB-12 Oral Delivery Developing under partnership arrangements (insulin, HGH)

[object Object],[object Object],[object Object],[object Object],[object Object],MuGard ™ - FDA Approved Treatment MuGard Demostrates Efficacy Versus Historical Control (standard of care) Product Launch Ongoing; Royalties Expected in 2009

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],ProLindac ™ Market Opportunity Positioning ProLindac as a Replacement for Sanofi-Aventis’ Eloxatin Represents a $3+ Billion Market Opportunity Tumor Model Efficacy vs. Eloxatin M5076 sarcoma (Pt-resistant) Markedly Superior B16 melanoma Markedly Superior 2008 ovarian xenograft Markedly Superior Colo-26 colon Superior HT-29 colon xenograft Superior HCT-116 colon xenograft Superior L1210 leukemia Superior 0157 Hybridoma Superior M5076 sarcoma Similar Lewis lung Similar P815 Mastocytoma Similar

ProLindac ™ - More Platinum, More Safely Unique design enables more platinum delivery, with fewer side effects Represents “equi-toxic” doses of ProLindac and Eloxatin DACH Platinum (same active in Eloxatin) is inactive while attached to polymer background Chelator releases platinum compound in low pH environment; e.g. tumor

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],ProLindac ™ - Phase 1/2 Trial Initial European Phase 1/2 Clinical Trial Suggests Efficacy With Improved Safety Profile Significant Drug Activity and Benign Toxicity Profile Warrants Further Development

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],ProLindac ™ Phase 2 Trial – Relapsed Ovarian Final Study Results – Safe and Active DACH Platinum Drug

[object Object],[object Object],[object Object],[object Object],Thiarabine – A Novel Nucleoside Analogue Significant Clinical Data Available – Ready for Phase 2 Trials

[object Object],[object Object],[object Object],[object Object],[object Object],Angiolix – On the heels of Avastin Monoclonal Antibody Therapy – Unique Target, Lactadherin

Cobalamin-coated Nanopolymer Platform The nanoparticle coated with Cobalamin (red) binds to intrinsic factor (1), which in turn binds to its cell surface receptor (2). The nanoparticle is transported across the cell (3), crosses the gut wall and enters the bloodstream (4). Using The Body’s Own Vitamin Absorption System To Enable and Enhance Delivery of Drugs Through Gut Wall The “Trojan Horse” Delivery Vehicle Nanopolymer “payload” can be Insulin, growth hormone, EPO, etc. 1 2 3 4

[object Object],[object Object],[object Object],[object Object],[object Object],Cobalamin-coated Nanopolymer Platform Cobalamin Enhanced Nanopolymers – Enabling Oral Insulin Sponsored Research Partnerships Ongoing Clinically Relevant Glucose Lowering Effect in Diabetic Rat Model

[object Object],[object Object],[object Object],[object Object],[object Object],Pexiganan – Novel Topical Antibiotic Large & Growing Markets; Late Stage Product; Actively Seeking Partners

[object Object],[object Object],[object Object],[object Object],EcoNail ™ – Onychomycosis Phase 2 Trial Completed – Seeking Development Partner

[object Object],[object Object],[object Object],[object Object],[object Object],Management Experienced Management Team

[object Object],[object Object],[object Object],[object Object],[object Object],Board of Directors Strong Board of Directors with Relevant Experience

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Financial Overview

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Milestones – 2009 and forward Significant News Flow Anticipated in 2009

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Conclusions – Investment Highlights ACCP – An Undervalued Investment Opportunity

Oncology Focused Company's Rich Pipeline and Partnering Strategy

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Oncology Focused Company's Rich Pipeline and Partnering Strategy

Similar to Oncology Focused Company's Rich Pipeline and Partnering Strategy (20)

Recently uploaded

Recently uploaded (20)

Oncology Focused Company's Rich Pipeline and Partnering Strategy